Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, Luis M. Ruilope, Peter Rossing, George L. Bakris, Christoph Tasto, Amer Joseph, Peter Kolkhof, Andrea Lage, Bertram Pitt
Summary: Finerenone reduces the incidence of new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, regardless of a history of HF.
Review
Endocrinology & Metabolism
Ralph A. DeFronzo, George L. Bakris
Summary: Chronic kidney disease (CKD) is the most common cause of kidney failure in patients with type 2 diabetes and is a major contributor to the global burden of disease. However, current treatment options have limited effectiveness in slowing CKD progression and reducing cardiovascular events. Recent studies have shown that finerenone, a non-steroidal mineralocorticoid receptor antagonist, is an effective treatment for slowing CKD progression and providing cardiovascular protection in patients with type 2 diabetes.
DIABETES OBESITY & METABOLISM
(2022)
Review
Cardiac & Cardiovascular Systems
Arjun K. Pandey, Deepak L. Bhatt, Francesco Cosentino, Nikolaus Marx, Ori Rotstein, Bertram Pitt, Ambirash Pandey, Javed Butler, Subodh Verma
Summary: Despite current treatment options, patients with heart failure and chronic kidney disease (CKD) remain at high risk for adverse outcomes and disease progression. Non-steroidal mineralocorticoid receptor antagonists (MRAs) have emerged as a new dimension in the treatment of cardiorenal disease, offering unique pharmacological properties and benefits. These agents have anti-inflammatory, anti-remodelling, and anti-fibrotic effects in the heart, kidneys, and blood vessels. Although there are several non-steroidal MRAs in development, only esaxerenone and finerenone have been approved globally.
EUROPEAN HEART JOURNAL
(2022)
Article
Transplantation
Rajiv Agarwal, Stefan D. Anker, George Bakris, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis Ruilope, Martin Gebel, Peter Kolkhof, Christina Nowack, Amer Joseph
Summary: Research has found that finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, can protect the kidneys and hearts of patients with chronic kidney disease and type 2 diabetes. The FIDELIO-DKD and FIGARO-DKD trials are investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes in T2D patients with different stages of kidney disease.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Stefan D. Anker, Bertram Pitt, Peter Rossing, Amer Joseph, Peter Kolkhof, Marc Lambelet, Robert Lawatscheck, George L. Bakris, Luis M. Ruilope, Rajiv Agarwal
Summary: This study found that finerenone can improve HF-related outcomes in patients with CKD and T2D, regardless of baseline eGFR and/or UACR categories.
JACC-HEART FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, Dimitrios Farmakis, Luis M. Ruilope, Peter Rossing, Johann Bauersachs, Robert J. Mentz, Peter Kolkhof, Charlie Scott, Amer Joseph, George L. Bakris, Stefan D. Anker
Summary: In the FIDELIO-DKD trial, finerenone improved cardiorenal outcomes in patients with CKD and T2D regardless of history of heart failure.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Article
Endocrinology & Metabolism
Hiddo J. L. Heerspink, Priya Vart, Niels Jongs, Brendon L. Neuen, George Bakris, Brian Claggett, Muthiah Vaduganathan, Finnian McCausland, Kieran F. Docherty, Pardeep S. Jhund, Scott D. Solomon, Vlado Perkovic, John J. V. McMurray
Summary: The combination treatment of SGLT2 inhibitors and MRA in patients with type 2 diabetes and CKD can significantly extend event-free survival and overall survival, with an estimated gain of 6.7 years in event-free survival compared to ACE inhibitors/angiotensin receptor blockers. This conclusion is supported by both trial data and observational study results. Even in a conservative scenario, the combination therapy still provides a substantial gain of 2.5 years in event-free survival.
DIABETES OBESITY & METABOLISM
(2023)
Article
Peripheral Vascular Disease
Luis M. Ruilope, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Pantelis Sarafidis, Roland E. Schmieder, Amer Joseph, Nicole Rethemeier, Christina Nowack, George L. Bakris
Summary: This analysis explored the relationship between office systolic blood pressure (SBP) and cardiorenal outcomes with finerenone in FIDELIO-DKD trial. Finerenone significantly reduced office SBP across all baseline SBP quartiles and improved cardiorenal outcomes. Reductions in office SBP accounted for a small proportion of the treatment effect on cardiorenal outcomes.
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, George L. Bakris, Bertram Pitt, Rajiv Agarwal, Peter Rossing, Luis M. Ruilope, Javed Butler, Carolyn S. P. Lam, Peter Kolkhof, Luke Roberts, Christoph Tasto, Amer Joseph, Stefan D. Anker
Summary: In the FIDELIO-DKD study, finerenone was found to reduce the risk of new-onset atrial fibrillation/flutter in patients with CKD and T2D. The effect on kidney or cardiovascular events was not significantly impacted by baseline history of atrial fibrillation/flutter.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Review
Urology & Nephrology
Peter Rossing
Summary: Chronic kidney disease (CKD) in type 2 diabetes is a serious problem that current treatments struggle to address. However, novel nonsteroidal mineralocorticoid receptor antagonists (MRAs) show promise in reducing proteinuria and markers of heart failure (HF), with a lower risk of hyperkalemia and renal impairment. Clinical trials have demonstrated the efficacy of the nonsteroidal MRA finerenone in delaying the progression of kidney and cardiovascular disease in CKD patients with type 2 diabetes. The use of nonsteroidal MRAs could be a beneficial addition to the treatment of CKD patients with type 2 diabetes.
KIDNEY INTERNATIONAL SUPPLEMENTS
(2022)
Article
Medicine, General & Internal
Tetiana A. Berezina, Zeljko Obradovic, Elke Boxhammer, Alexander A. A. Berezin, Michael Lichtenauer, Alexander E. E. Berezin
Summary: The study aimed to detect the predictive value of adropin levels in serum for CKD grades 1-3 in T2DM patients with chronic HF. The results showed that patients with lower adropin levels were more likely to develop CKD. This indicates that adropin levels may serve as an independent predictor for CKD.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Cosimo Cosimato, Thomas Agoritsas, Thomas A. Mavrakanas
Summary: MRA can reduce cardiovascular morbidity and mortality in patients with heart failure and ischemic heart disease, and also have been used in patients with diabetic nephropathy to control proteinuria. Currently, guidelines recommend against the use of MRAs in patients with advanced CKD, but there is growing interest in their use in this population.
PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Medicine, General & Internal
Monarch Shah, Alaa S. Awad, Emaad M. Abdel-Rahman
Summary: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, shows promising therapeutic effects in heart failure and chronic kidney disease. Clinical trials demonstrate its efficacy in improving kidney and cardiovascular outcomes, particularly in patients with CKD and T2DM.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Stefan D. Anker, Bertram Pitt, Darren K. McGuire, Peter Rossing, Luis M. Ruilope, Javed Butler, Ewa A. Jankowska, Erin D. Michos, Dimitrios Farmakis, Alfredo E. Farjat, Peter Kolkhof, Andrea Scalise, Amer Joseph, George L. Bakris, Rajiv Agarwal
Summary: Finerenone consistently reduces the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of their history of atherosclerotic cardiovascular disease.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Amanda R. Buckallew, Katie B. Tellor, Rachel Watson, William Miller, Gina Mbachu, Cameron Whitlock, Jay R. Seltzer, Anastasia L. Armbruster
Summary: This study evaluated the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease, suggesting that spironolactone may be safely initiated in hospitalized patients with these conditions. However, the appropriateness of therapy should be assessed upon admission to the hospital.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Agata Tyminska, Krzysztof Ozieranski, Marek Wawrzacz, Pawel Balsam, Cezary Maciejewski, Magdalena Kleszczewska, Magdalena Zawadzka, Michal Marchel, Maria G. Crespo-Leiro, Aldo P. Maggioni, Jaroslaw Drozdz, Grzegorz Opolski, Marcin Grabowski, Agnieszka Kaplon-Cieslicka
Summary: Heart rate control in patients with heart failure after hospitalization is unsatisfactory, possibly due to inadequate doses of beta-blockers and neglect of other heart rate lowering drugs.
CARDIOLOGY JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Suleman Aktaa, Gorav Batra, Stefan K. James, Daniel J. Blackman, Peter F. Ludman, Mamas A. Mamas, Mohamed Abdel-Wahab, Gianni D. Angelini, Martin Czerny, Victoria Delgado, Giuseppe De Luca, Agricola Eustachio, Dan Foldager, Christian W. Hamm, Bernard Iung, Norman Mangner, Julinda Mehilli, Gavin J. Murphy, Darren Mylotte, Radoslaw Parma, Anna Sonia Petronio, Bodgan A. Popescu, Lars Sondergaard, Rui C. Teles, Manel Sabate, Christian J. Terkelsen, Luca Testa, Jianhua Wu, Aldo P. Maggioni, Lars Wallentin, Barbara Casadei, Chris P. Gale
Summary: The EuroHeart project aims to create pan-European data standards for cardiovascular diseases and interventions, including TAVI, to quantify quality of care and patient outcomes.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
(2023)
Article
Cardiac & Cardiovascular Systems
Gorav Batra, Suleman Aktaa, A. John Camm, Francisco Costa, Luigi Di Biase, David Duncker, Laurent Fauchier, Nikolaos Fragakis, Lars Frost, Ziad Hijazi, Tord Juhlin, Jose Luis Merino, Lluis Mont, Jens Cosedis Nielsen, Jonas Oldgren, Anna Polewczyk, Tatjana Potpara, Frederic Sacher, Philipp Sommer, Roland Tilz, Aldo P. Maggioni, Lars Wallentin, Barbara Casadei, Chris P. Gale
Summary: This study aimed to develop standardized data definitions for atrial fibrillation/flutter (AF/AFL) and catheter ablation. Through a systematic literature review and expert consensus, a total of 70 mandatory variables and 92 additional variables were established. The development of these standards will help improve the quality of care, facilitate international observational research, and enable post-marketing surveillance.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
(2023)
Article
Cardiac & Cardiovascular Systems
Camilla Fuchs Andersen, Massar Omar, Andreas Glenthoj, Daniel El Fassi, Holger J. Moller, Jorgen A. Lindholm Kurtzhals, Bjarne Styrishave, Caroline Kistorp, Christian Tuxen, Mikael K. Poulsen, Jens Faber, Lars Kober, Finn Gustafsson, Jacob E. Moller, Morten Schou, Jesper Jensen
Summary: This study aimed to investigate the early effect of empagliflozin on erythropoiesis and iron metabolism in patients with heart failure with reduced ejection fraction. The results showed that empagliflozin increased erythropoiesis and enhanced early iron utilization, which may contribute to the cardioprotective properties of empagliflozin.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Daniel Modin, Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Brian L. Claggett, Erica L. Dueger, Sandrine I. Samson, Matthew M. Loiacono, Lars Kober, Scott D. Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen
Summary: Digital behavioral nudges, such as electronic letters, emphasizing the potential cardiovascular benefits of influenza vaccination and using a reminder letter strategy, were found to be effective in increasing influenza vaccine uptake among older adults both with and without cardiovascular disease.
Article
Cardiac & Cardiovascular Systems
Pooja Dewan, Joao Pedro Ferreira, Jawad H. Butt, Mark C. Petrie, William T. Abraham, Akshay S. Desai, Kenneth Dickstein, Lars Kober, Milton Packer, Jean L. Rouleau, Simon Stewart, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Pardeep S. Jhund, John J. V. McMurray
Summary: This study aims to examine the risk related to comorbidities in heart failure patients, both at individual and population levels. It compares the risk of individual comorbidities and their combinations, and analyzes the interaction between different comorbidities.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Medicine, General & Internal
Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S. Bhatt, Simin Gharib Lee, Daniel Modin, Brian L. Claggett, Erica L. Dueger, Sandrine Samson, Matthew M. Loiacono, Lars Kober, Scott Solomon, Pradeesh Sivapalan, Jens Ulrik Staehr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sorensen
Summary: This study investigated whether behavioural nudges delivered via a governmental electronic letter system could increase influenza vaccination uptake among older adults in Denmark. The results showed that sending an electronic letter highlighting potential cardiovascular benefits of vaccination or sending repeated letters at randomisation and at day 14 significantly improved vaccination rates.
Article
Cardiac & Cardiovascular Systems
Soren Zoega Diederichsen, Lucas Yixi Xing, Diana My Frodi, Emilie Katrine Kongebro, Ketil Jorgen Haugan, Claus Graff, Soren Hojberg, Derk Krieger, Axel Brandes, Lars Kober, Jesper Hastrup Svendsen
Summary: There is a growing interest in heart rhythm monitoring and the detection of subclinical atrial fibrillation (AF) which may identify cases of bradyarrhythmias. This study aimed to assess the prevalence and prognostic significance of bradyarrhythmias in individuals screened for AF using an implantable loop recorder (ILR). The results showed that more than 1 in 5 individuals over the age of 70 with cardiovascular risk factors can be diagnosed with bradyarrhythmias when long-term continuous monitoring for AF is applied. ILR screening led to a significant increase in the diagnosis of bradyarrhythmias and pacemaker implantations compared with usual care, but there was no change in the risk of syncope or sudden death.
Article
Cardiac & Cardiovascular Systems
Andrew S. Perry, Aldo P. Maggioni, Luigi Tavazzi, Wayne C. Levy
Summary: This study aimed to investigate the association between beta-blocker therapy and survival in heart failure patients with pacemaker rhythm. The analysis of GISSI-HF trial data showed that beta-blocker therapy was significantly associated with improved survival, especially in patients with baseline pacemaker rhythm.
Editorial Material
Cardiac & Cardiovascular Systems
Massimo Iacoviello, Marco Marini, Mauro Gori, Francesco Orso, Lucio Gonzini, Marco Gorini, Peter Fenici, Aldo Pietro Maggioni
Summary: Randomised clinical trials, observational studies, and meta-analyses have shown that SGLT2 inhibitors can reduce the risk of heart failure, chronic kidney disease progression, and mortality in patients, regardless of the presence of type 2 diabetes. The aim of this study was to assess the eligibility of HF patients in the Italian Network on Heart Failure registry for inclusion in the DAPA-HF study. The results showed that 73% of cardiology patients were eligible for the DAPA-HF study.
Article
Cardiac & Cardiovascular Systems
Caroline Sindet-Pedersen, Felix Michalik, Jarl Emanuel Strange, Daniel Molager Christensen, Nina Nouhravesh, Thomas Alexander Gerds, Charlotte Andersson, Fredrik Folke, Tor Biering-Sorensen, Emil Fosbol, Christian Torp-Pedersen, Gunnar H. Gislason, Lars Kober, Morten Schou
Summary: This study investigates the association between mRNA vaccines and the risks of all-cause mortality, worsening heart failure, venous thromboembolism, and myocarditis in patients with heart failure. The findings suggest that receiving an mRNA vaccine is not associated with an increased risk of these outcomes.
CIRCULATION-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
M. P. Bonaca, E. Lesen, E. Giannitsis, J. Hedberg, T. Jernberg, D. Lambrelli, M. Duong, A. P. Maggioni, A. Ariza-Sole, J. ten Berg, R. F. Storey
Summary: This study provides insights into the real-world utilization of ticagrelor 60 mg in patients with prior myocardial infarction (MI) and its associated bleeding and ischemic outcomes. The observed event rates align with those in pivotal trials, reaffirming the safety profile of ticagrelor and highlighting the significant residual ischemic risk in this population.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Jeppe Kofoed Petersen, Emil Loldrup Fosbol, Jarl Emanuel Strange, Morten Schou, Daniel Alexander Brems, Lars Kober, Lauge Ostergaard
Summary: This study examines the impact of first-time detected atrial fibrillation (AF) after transcatheter aortic valve replacement (TAVR) on mortality and heart failure (HF). The findings suggest that first-time detected AF may have similar implications for patients' health as AF with a previous history.
IJC HEART & VASCULATURE
(2023)
Correction
Cardiac & Cardiovascular Systems
James P. Curtain, Carly Adamson, Toru Kondo, Jawad Haider Butt, Akshay S. Desai, Faiez Zannad, Jean L. Rouleau, Luis E. Rohde, Lars Kober, Inder S. Anand, Dirk J. van Veldhuisen, Michael R. Zile, Martin P. Lefkowitz, Scott DSolomon, Milton Packer, Mark C. Petrie, Pardeep S. Jhund, John J. V. McMurray
EUROPEAN HEART JOURNAL
(2023)
Correction
Cardiac & Cardiovascular Systems
Anna Gundlund, Lars Kober, Dan E. Hofsten, Morten Vester-Andersen, Maria W. Pedersen, Christian Torp-Pedersen, Kristian Kragholm, Peter Sogaard, Morten Smerup, Emil L. Fosbol
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
(2023)